United BioSource Corporation (UBC) partnered with Singapore-based Clearstate, a market intelligence firm focused on the healthcare and pharmaceutical industry. Through this partnership, UBC will offer market access, pricing and reimbursement strategies for drug and device manufacturers in the Asia-Pacific region.
“We are extremely pleased to partner with Clearstate to offer comprehensive market access strategies throughout the Asia-Pacific region,” said Lisbet Coulton, UBC’s director of international pricing and reimbursement. “As life science companies expand their operations throughout the Asia-Pacific region, UBC and Clearstate are ideally positioned to support their products. Our clients have been delighted with the insight and expertise provided by Clearstate and we believe our partnership offers significant value for companies seeking effective market access solutions in this region.”
UBC opened its first office in Asia-Pacific in February. This Tokyo office will have a staff of 12 by the end of the year, according to UBC CEO Ethan Leder. Leder told CenterWatch earlier this year that the Asia-Pacific region has grown increasingly important to UBC as both regional and worldwide clients have requested increased services there.
“We’ve been doing work for Japanese companies for a long time, and they’re some of our best customers—in both the rest of world and in Japan,” Leder said. “We felt it was important—not just with those Japanese companies but with some of the other ex-Japan companies that are developing drugs and marketing drugs in-country—to be on the ground.”